Bicara Therapeutics Inc [BCAX] stock is trading at $18.03, up 5.81%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BCAX shares have gain 29.99% over the last week, with a monthly amount glided 49.50%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bicara Therapeutics Inc [NASDAQ: BCAX] stock has seen the most recent analyst activity on August 19, 2025, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $36. Previously, Wells Fargo upgraded its rating to Equal Weight on May 23, 2025, and kept the price target unchanged to $8. On April 17, 2025, Wells Fargo initiated with a Underweight rating and assigned a price target of $8 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $31 on February 06, 2025. H.C. Wainwright initiated its recommendation with a Buy and recommended $42 as its price target on December 06, 2024. Rodman & Renshaw started tracking with a Buy rating for this stock on November 05, 2024, and assigned it a price target of $48. In a note dated October 08, 2024, TD Cowen initiated an Buy rating.
Bicara Therapeutics Inc [BCAX] stock has fluctuated between $7.80 and $28.09 over the past year. Currently, Wall Street analysts expect the stock to reach $24 within the next 12 months. Bicara Therapeutics Inc [NASDAQ: BCAX] shares were valued at $18.03 at the most recent close of the market. An investor can expect a potential return of 33.11% based on the average BCAX price forecast.
Analyzing the BCAX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.22 and Total Capital is -0.28. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.06 points at the first support level, and at 16.09 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.63, and for the 2nd resistance point, it is at 19.23.
Ratios To Look Out For
For context, Bicara Therapeutics Inc’s Current Ratio is 25.80. Further, the Quick Ratio stands at 25.80, while the Cash Ratio is 25.34.
Transactions by insiders
Recent insider trading involved Cohlhepp Ryan, Officer, that happened on Oct 06 ’25 when 39600.0 shares were purchased. Officer, Hyep Ivan completed a deal on Oct 06 ’25 to buy 6514.0 shares. Meanwhile, Chief Legal Officer Meisner Lara sold 33807.0 shares on Sep 29 ’25.
